Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
Clinical and Applied Thrombosis/Hemostasis, 2019 Heparin and its low-molecular-weight heparin derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications, including kidney dialysis, cardiopulmonary bypass, and in the management of venous ...
Jianle Chen BS +13 more
doaj +1 more source
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
Frontiers in Pharmacology, 2020 Background Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (
P. Paolisso +13 more
semanticscholar +1 more source
Cost-effectiveness of mechanical thromboprophylaxis for cesarean deliveries in Brazil.
PLoS ONE, 2023 ObjectiveTo evaluate the cost-effectiveness of using mechanical thromboprophylaxis for patients undergoing a cesarean delivery in Brazil.MethodsA decision-analytic model built in TreeAge software was used to compare the cost and effectiveness of ...
Alex Veloz +4 more
doaj +3 more sources
Low-Molecular-Weight Heparin–Induced Skin Necrosis Without Thrombocytopenia
Annals of Internal Medicine: Clinical Cases, 2023 Heparin-induced skin necrosis is an immune-based entity that appears secondary to exposure to unfractionated heparin or low-molecular-weight heparin, consisting of the appearance of erythematous lesions that can progress to necrosis at the point of ...
Ana Quiles-Recuenco +4 more
doaj +1 more source
Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]
, 2017 Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M. +10 more
core +2 more sources
The anti-cancer properties of heparin and its derivatives: a review and prospect
Cell Adhesion & Migration, 2020 Heparin, including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and heparin derivatives, are commonly used in venous thromboembolism treatment and reportedly have beneficial effects on cancer survival.
Sai-Nan Ma +8 more
doaj +1 more source
Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis [PDF]
, 2018 Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience.
Benelhaj, Naima B. +5 more
core +1 more source
Thrombosis Research, 2019 INTRODUCTION It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE).
Ang Li, D. Garcia, G. Lyman, M. Carrier
semanticscholar +1 more source
Gynecology Obstetrics & Reproductive Medicine, 2019 Heparin-induced thrombocytopenia is a rare and life-threatening condition of exposure to heparin. A case of heparin-induced thrombocytopenia due to the low molecular weight heparin was presented.
Yasin Durmuş +8 more
doaj +1 more source
Anticoagulants for acute ischaemic stroke [PDF]
, 2015 Peer reviewedPublisher ...
Counsell, Carl +2 more
core +1 more source